MX2021013010A - Composiciones y metodos para modular la actividad del complemento. - Google Patents

Composiciones y metodos para modular la actividad del complemento.

Info

Publication number
MX2021013010A
MX2021013010A MX2021013010A MX2021013010A MX2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A MX 2021013010 A MX2021013010 A MX 2021013010A
Authority
MX
Mexico
Prior art keywords
methods
complement
release formulations
modulate
compositions
Prior art date
Application number
MX2021013010A
Other languages
English (en)
Spanish (es)
Inventor
Hong Wang
Evan Thackaberry
Simon J Read
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of MX2021013010A publication Critical patent/MX2021013010A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021013010A 2019-04-24 2020-04-24 Composiciones y metodos para modular la actividad del complemento. MX2021013010A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962837978P 2019-04-24 2019-04-24
US201962947183P 2019-12-12 2019-12-12
US201962947188P 2019-12-12 2019-12-12
PCT/US2020/029733 WO2020219822A1 (en) 2019-04-24 2020-04-24 Compositions and methods for modulating complement activity

Publications (1)

Publication Number Publication Date
MX2021013010A true MX2021013010A (es) 2022-01-18

Family

ID=70977557

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013010A MX2021013010A (es) 2019-04-24 2020-04-24 Composiciones y metodos para modular la actividad del complemento.

Country Status (13)

Country Link
US (1) US20220211799A1 (enExample)
EP (1) EP3958842A1 (enExample)
JP (2) JP7726791B2 (enExample)
KR (1) KR20220004039A (enExample)
CN (1) CN113710230A (enExample)
AU (1) AU2020261059A1 (enExample)
BR (1) BR112021017820A2 (enExample)
CA (1) CA3137895A1 (enExample)
IL (1) IL287079A (enExample)
MX (1) MX2021013010A (enExample)
SG (1) SG11202109837SA (enExample)
TW (1) TW202106290A (enExample)
WO (1) WO2020219822A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2016009612A0 (en) 2014-06-12 2016-12-31 Ra Pharmaceuticals Inc Modulation of complement activity
HRP20211824T1 (hr) 2015-01-28 2022-03-04 Ra Pharmaceuticals, Inc. Modulatori aktivnosti komplementa
HUE061759T2 (hu) 2015-12-16 2023-08-28 Ra Pharmaceuticals Inc Komplement aktivitás modulátorai
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
CN113226368A (zh) * 2018-10-22 2021-08-06 Ra制药公司 采用齐鲁考普的神经疾病治疗

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241139A (zh) * 1996-12-20 2000-01-12 武田药品工业株式会社 生产缓释制剂的方法
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
MXPA05011886A (es) 2003-05-15 2006-02-17 Tanox Inc Metodos y composiciones para la prevencion y tratamiento de septicemia.
CN1289066C (zh) * 2003-09-18 2006-12-13 中国人民解放军第二军医大学 胰高血糖素样肽－1缓释微球制剂及其用途
US20060270590A1 (en) 2005-03-29 2006-11-30 Lockwood Samuel F Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
EP1885398B1 (en) 2005-05-26 2015-07-08 The Regents of the University of Colorado, a body corporate Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
MX2008004094A (es) 2005-09-27 2009-02-27 Efrat Biopolymers Ltd Composiciones de polimero inyectables hidrofobicas, gelificantes.
SI2500030T2 (sl) 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
WO2007074010A1 (en) * 2005-12-24 2007-07-05 Teagasc Dairy Products Research Centre Process for the production of trans-10, cis 12 octadecadienoic acid
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
WO2008044928A1 (en) 2006-10-10 2008-04-17 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
MX2009009738A (es) 2007-04-30 2009-09-24 Alcon Res Ltd Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento.
BRPI0812767A2 (pt) 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
DK2205624T3 (da) 2007-10-27 2017-01-02 Corden Pharma Colorado Inc Insulinotropisk peptidsyntese under anvendelse af faststof- og opløsningsfasekombinationsteknikker
WO2010025510A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CN106390117A (zh) 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
US20110269807A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
US20150330989A1 (en) 2012-11-15 2015-11-19 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
WO2015103319A1 (en) * 2013-12-31 2015-07-09 Heron Therapeutics, Inc. Polymer-based compositions for extended release of proteins
AP2016009612A0 (en) * 2014-06-12 2016-12-31 Ra Pharmaceuticals Inc Modulation of complement activity
WO2016138520A1 (en) 2015-02-27 2016-09-01 The Johns Hopkins University Assay to diagnose and treat disorders of the alternative pathway of complement activation
HUE061759T2 (hu) 2015-12-16 2023-08-28 Ra Pharmaceuticals Inc Komplement aktivitás modulátorai
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
IL261809B2 (en) * 2017-04-03 2024-04-01 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5A activity

Also Published As

Publication number Publication date
KR20220004039A (ko) 2022-01-11
CA3137895A1 (en) 2020-10-29
US20220211799A1 (en) 2022-07-07
AU2020261059A1 (en) 2021-10-14
JP2022530042A (ja) 2022-06-27
SG11202109837SA (en) 2021-10-28
BR112021017820A2 (pt) 2022-02-08
IL287079A (en) 2021-12-01
JP2025118607A (ja) 2025-08-13
TW202106290A (zh) 2021-02-16
EP3958842A1 (en) 2022-03-02
JP7726791B2 (ja) 2025-08-20
CN113710230A (zh) 2021-11-26
WO2020219822A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
MX2021013010A (es) Composiciones y metodos para modular la actividad del complemento.
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2021015668A2 (es) Moduladores de la vía integrada del estrés
CL2021000741A1 (es) Composiciones plaguicidas sinérgicas y métodos para distribución de ingredientes activos insecticidas
CL2022000354A1 (es) Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos
CL2020001990A1 (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1991-20)
CO2022014137A2 (es) Inhibidores de rip1k
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2020001991A1 (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1990-20)
CL2019002810A1 (es) Compuestos inhibidores de ask1 y usos de los mismos.
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2022000998A1 (es) Inhibidores de las cinasas raf
BR112022010754A2 (pt) Análogos de rapamicina e usos dos mesmos
ECSP19084085A (es) Inhibidores pirazólicos de magl
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
MX2022000646A (es) Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms).
CO2017011958A2 (es) Benzamidas sustituidas y métodos para utilizarlas
CL2012000013A1 (es) Compuestos derivados de 4-{3-[3-(4-trifluorometil-fenil)ureido]-5-fluoro-bencilamino}-1h-pirazol-3-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y su uso como moduladores de la actividad de las proteinas quinasa para el tratamiento del cancer.
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
MX2021008941A (es) Moduladores gpr35.
MX2023010491A (es) Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis.